While I suspect you are just trolling, this is a reasonable question so I will answer it. The reason it was not registered in the USA is Lederle Laboratories (American Cyanamid) was looking to register Bisantrene in the USA for breast cancer. They weren’t really interested in AML as a market as back in the 1990s the AML market was tiny and the amount you could change for a drug like Bisantrene was not very high. Lederle for reason only known to themselves (I suspect due to interest from clinicians) ran the leukaemia trials in Europe and the breast cancer trials in the USA.
Unfortunately for them, they managed to mess up the dosage in the Phase III breast cancer trial making it unregisterable without running a new Phase III trial. Once this happened they decide to drop the registration of Bisantrene in France - the returns from an AML drug in France alone would not cover the cost of keeping the drug on the market. Such is the way these things go at times.
MST valuation of RAC, page-223
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |